Clinical Trial RTOG 1114
- Phase II Randomized Study of Rituximab, Methotrexate, Procarbazine, Vincristine & Cytarabine with and without Low-Dose Whole-Brain Radiotherapy for Primary Central Nervous System Lymphoma
- Principal Investigator
- Jeffrey Raizer
- Status: Accepting New Patients
- Study Type: Therapeutic, Treatment
- Protocol No:.RTOG 1114
- This is a randomized investigational study is to determine the effects, good and/or bad, of the combination of low-dose whole brain radiation plus chemotherapy on PCNSL (Primary Central Nervous System Lymphoma) and tumor versus chemotherapy alone.
- PCNSL can be cured in less than half of patients with a combination of chemotherapy and standard brain radiation. Unfortunately, the combination of chemotherapy and standard brain radiation may cause serious damage to the brain, such as progressive memory and neurologic problems that can be fatal. As a new alternative, radiotherapy has been used in significantly lower doses. In a previous study, this seemed to achieve the same rates of cure as full doses of radiotherapy but with much less risk of neurologic side effects.
Some of the eligibility criteria include:
- Participants must have B-cell non-Hodgkin's lymphoma involving the brain with no evidence of systemic involvement.
- Participants must be 18 years of age or older.
- Participants must not have had prior chemotherapy for CNS lymphoma or prior brain/cranial irradiation.
- Description of Treatment
- Participants on this study will be "randomized" into one of two study groups. Participants in both ARMs (1 and 2) will receive chemotherapy with rituximab, methotrexate (MTX), procarbazine, and vincristine. The treatment will be broken up into 28-day periods called cycles. Participants will have 4 cycles on this chemotherapy regimen. After the 4 cycles, participants in Arm 1 will receive two 28-day cycles of chemotherapy with Cytarabine. Participants in ARM 2, if there is no tumor growth (of existing tumor) during the chemotherapy, will then receive the reduced-dose radiation therapy to their brain daily for a total of 13 days. After completion of the radiation therapy, ARM 2 participants will receive two 28-day cycles of chemotherapy with Cytarabine.
- Sara Duffey
Clinical Research and Education Specialist
Robert H. Lurie Comprehensive Cancer Center
Find Related Clinical Trials
Browse by Disease Sites
Other Clinical Trials by Jeffrey Raizer
- A Phase II Randomized Trial Comparing the Efficacy of Heat Shock Protein-Peptide Complex-96 (HSPPC-96)(NSC #725085, Alliance IND#15380) Vaccine Given with Bevacizumab Versus Bevacizumab Alone in the Treatment of Surgically Resectable Recurrent Glioblastoma Multiforme (GBM)
- A Phase 2, Multicenter, Open-Label Study Of BGJ398 in Patients with Recurrent Resectable or Unresectable Glioblastoma
- Phase Ib/II multicenter study of buparlisib plus carboplatin or lomustine in patients with recurrent glioblastoma multiforme (GBM)
- An International, Randomized, Double-Blind, Controlled Study of Rindopepimut/GM-CSF with Adjuvant Temozolomide in Patients with Newly Diagnosed, Surgically Resected, EGFRvIII-positive Glioblastoma
- An Open Label Phase 1b/2 Study of Orally Administered PLX3397 in Combination with Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma
- A Phase 1/2 Study of SL-701, a Subcutaneously Injected Multivalent Glioma-Associated Antigen Vaccine, in Adult Patients with Recurrent Glioblastoma Multiforme
- A Phase II Study of the Efficacy of Hypofractionated Radiation Therapy with Bevacizumab and Temozolomide Followed by Maintenance Temozolomide and Bevacizumab for Recurrent High-Grade Gliomas
- A Phase I-II trial Everolimus and Sorafenib in Patients with Recurrent High-Grade Gliomas BTTC09-01
- BTTC11-01: Randomized, Double-Blind, Placebo-Controlled Trial of Lacosamide for Seizure Prophylaxis in Patients with High-Grade Gliomas
- Phase I/II Adaptive Randomized Trial of Bevacizumab versus Bevacizumab plus Vorinostat in Adults with Recurrent Glioblastoma (BTTC11-02)
- A Phase II Trial of Oral Pazopanib plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A) without Prior Bevacizumab Exposure and (B) after Failing Prior Bevacizumab
- Natural History of Postoperative Cognitive Function, Quality Of Life, and Seizure Control in Patients with Supratentorial Low-Risk Grade II Glioma
- Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab with or without AMG 386 in Patients with Recurrent Glioblastoma or Gliosarcoma
last updated: 25-Jul-14 09:56 AM
Clinical trial availability changes frequently. Please check this site often for updates or call 312.695.1102 for personal assistance.